AI pathology tool measures lung cancer treatment response after neoadjuvant chemoimmunotherapy with 91% accuracy, speeding NSCLC care while needing review for complete response. An artificial ...
Lung cancer drug doubles survival, showing 18.5 months median overall survival versus 10 months with chemotherapy in a key trial.
Artificial intelligence (AI) tools can help physicians predict treatment and survival outcomes in patients with advanced ...
Despite the revolutionary impact of immune checkpoint inhibitors on cancer therapy, 60% to 80% of patients with NSCLC still ...
New results from the global Phase I/II ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with ...
BioNTech and partner OncoC4's anti-CTLA-4 immunotherapy gotistobart almost doubled survival in a trial involving patients with a hard-to-treat form of lung cancer, ahead of a pivotal readout due next ...
Gotistobart continues to show potential aschemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with ...
First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with ...
Randomized Phase III Trial for Evaluating the Efficacy of Adjuvant Abemaciclib in Patients With Locoregional Recurrence of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative ...
Neoadjuvant and perioperative immunotherapy have redefined the treatment landscape for select patients with early-stage and locally-advanced resectable non-small cell lung cancer (NSCLC). Immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results